Advertisement

Search Results

Advertisement



Your search for all items matches 20543 pages

Showing 1 - 50


pancreatic cancer
supportive care

2019 Supportive Care: Racial Disparities in Use of Hospice Care Near Death Among Patients With Pancreatic Cancer

Despite advances in the detection and management of pancreatic cancer, the disease remains difficult to treat and is among the deadliest of all cancers. About 56,770 men and women will be diagnosed with pancreatic cancer in 2019, with African American patients being disproportionately affected by...

Expert Point of View: Sibylle Loibl, MD, and Nadia Harbeck, MD, PhD

Chair of the German Breast Group, Sibylle Loibl, MD, of the University of Frankfurt, commented as a formal discussant of MONALEESA-3 and MONARCH 2. “It’s great to see overall survival in the first- and second-line metastatic breast cancer settings. We haven’t seen that in many years,” she said....

breast cancer

Landmark Studies Show Clear Overall Survival Benefit for CDK4/6 Inhibitors in Advanced Breast Cancer

CDK4/6 inhibitors clearly improve overall survival in advanced breast cancer, as this prized endpoint was robustly demonstrated in two landmark phase III trials reported at the European Society for Medical Oncology (ESMO) Congress 2019. Dennis J. Slamon, MD, PhD, of the University of California,...

immunotherapy
leukemia

Debating the Role of Chemoimmunotherapy in the First-Line Setting of CLL

The advent of new targeted agents for chronic lymphocytic leukemia (CLL) has ushered in a golden age of treatment, leading to longer, more durable periods of disease control. Not all oncologists are convinced, however, that improvements in progression-free survival alone warrant dispensing with...

The Future of the Radiation Abscopal Response

“Two roads diverged in a wood, and I—I took the one less traveled by,And that has made all the difference.” –Robert Frost One of the first patients I encountered after residency was a 26-year-old woman with a single brain metastasis from melanoma. For anonymity, let’s call her Anna. Anna had just...

Cancer Researcher Mary J.C. Hendrix, PhD, Returns to West Virginia to Lead Her Alma Mater

Nationally regarded melanoma researcher Mary J.C. Hendrix, PhD, was born in La Jolla, California, a seaside community surrounded by ocean bluffs and beaches within the city of San Diego. She was reared in a Navy family that moved from the West Coast to the East Coast during her childhood,...

lymphoma
immunotherapy

Role of Radiotherapy for Patients With Refractory Lymphoma Receiving CAR T-Cell Therapy

Although the role of radiotherapy in chimeric antigen receptor (CAR) T-cell therapy for lymphoma is still evolving, radiotherapy “would be an ideal bridging therapy” for patients with chemorefractory diffuse large B-cell lymphoma, stated George Mikhaeel, MD, Professor of Radiation Oncology and...

gynecologic cancers

Three Phase III Trials Suggest Paradigm Shift With PARP Inhibitors in Ovarian Cancer

Ovarian cancer is typically a second-tier newsmaker at the world’s premier oncology conferences, but at the European Society for Medical Oncology (ESMO) Congress 2019, this tumor type generated universal buzz. Impressive findings were presented for three PARP inhibitors in front-line maintenance...

Expert Point of View: Sherene Loi, MD, PhD

Formal discussant Sherene Loi, MD, PhD, Professor of Cancer Therapeutics at the Peter MacCallum Cancer Centre, Melbourne, Australia, characterized the results of KEYNOTE-522 as “exciting.” “This is the first phase III neoadjuvant study in triple-negative breast cancer. Despite breast cancer not...

breast cancer
immunotherapy

Phase III Evidence Supports Neoadjuvant Immunotherapy Plus Chemotherapy for Early Triple-Negative Breast Cancer

Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. The addition of the checkpoint...

Expert Point of View: Kelvin Kar-Wing Chan, MD, PhD

Kelvin Kar-Wing Chan, MD, PhD, a medical oncologist and Associate Scientist at Odette Sunnybrook Health Sciences Centre, Toronto, commented that from the patient’s perspective, rising cancer costs can lead to financial hardship, whether material (ie, medical debts and bankruptcy) or psychological...

lung cancer

Out-of-Pocket Costs for Oral Tyrosine Kinase Inhibitors and Survival in Advanced Lung Cancer

Tyrosine kinase inhibitors have changed the paradigm of care for advanced EGFR- and ALK-positive non–small cell lung cancer (NSCLC), but not all patients taking these drugs may receive the same benefit. The results of a recent retrospective analysis suggest that higher out-of-pocket costs for...

immunotherapy

Algorithm for Identifying Genetic Mutations Likely to Respond to Immunotherapy

A new model works to determine which genetic mutations may respond best to treatment with immunotherapy. Richman et al published the data on the model’s development in Cell Systems, and the algorithm, antigen.garnish, is already available online as an open source technology to serve as a resource. ...

solid tumors
immunotherapy

Pegilodecakin Plus Pembrolizumab or Nivolumab in Advanced Solid Tumors

In a phase Ib trial reported in The Lancet Oncology, Naing et al found that the combination of pegilodecakin (pegylated interleukin [IL]-10) with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab or nivolumab was active in previously treated advanced solid tumors.  In the study,...

skin cancer

No Survival Benefit With Complete Lymph Node Dissection vs Observation in Sentinel Node–Positive Melanoma

As reported by Leiter et al in the Journal of Clinical Oncology, the final analysis of the German phase III DeCOG-SLT trial have shown no distant metastasis-free survival, recurrence-free survival, or overall survival benefit with complete lymph node dissection vs observation in patients with...

prostate cancer

Apalutamide Treatment for Metastatic Castration-Sensitive Prostate Cancer and Health-Related Quality of Life

In an analysis of the phase III TITAN trial reported in The Lancet Oncology, Neeraj Agarwal, MD, and colleagues found that that treatment with apalatuamide was associated with preserved health-related quality of life, including pain and fatigue outcomes, in patients with metastatic...

issues in oncology

Exercise for Patients With Cancer to Minimize Treatment Cardiotoxicity

Tailored exercise may help to minimize cardiotoxicity in patients with cancer, according to a report published by D’Ascenzi et al in the European Journal of Preventive Cardiology. Cardiovascular diseases are common side effects in patients with cancer. This is the result of cardiotoxicity, whereby...

lymphoma
symptom management

FDA Pipeline: Designations for Acute Graft-vs-Host Disease, Peripheral T-Cell Lymphoma

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a therapy for steroid-refractory acute graft-vs-host disease and granted Orphan Drug designation to a therapy for peripheral T-cell lymphoma. Fast Track Designation for T-Guard in Steroid-Refractory Acute...

head and neck cancer
issues in oncology

Effect of Patient General Preference for More vs Less Medical Care on Intensity of Posttreatment Thyroid Cancer Surveillance

In an analysis reported in the Journal of Clinical Oncology, Evron et al found that patients with thyroid cancer who were declared disease-free after initial treatment were more likely to have increased numbers of physician visits and imaging tests if they reported a generalized preference for...

breast cancer
geriatric oncology

Pooled Analysis of Outcomes in Older Women With Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Plus Aromatase Inhibitor Therapy

In a U.S. Food and Drug Administration (FDA) pooled analysis reported in the Journal of Clinical Oncology, Howie et al found that progression-free survival and benefit were similar for older vs younger postmenopausal women treated with combined cyclin-dependent kinase 4/6 (CDK4/6) plus aromatase...

Selected Breast Cancer Abstracts From ESMO 2019

This week, we’ll be discussing selected breast cancer abstracts presented at the ESMO Congress 2019, including the MONALEESA-3 and MONARCH 2 studies of CDK4/6 inhibitors for advanced breast cancer; the BROCADE 3 trial of veliparib plus carboplatin and paclitaxel in some advanced BRCA-mutated breast ...

issues in oncology

Virtual Molecular Tumor Boards May Help to Efficiently Deliver Precision Medicine to Patients

Using virtual, cloud-based, interconnected computing techniques applied to 51,000 variables, researchers reduced the time needed to assess a patient’s tumor profile and suitability for clinical trials from 14 to 4 days. This method also increased the number of cases that could be assessed compared...

lung cancer

IASLC North America: Lung Cancer Screening Among First Responders

National lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders, according to a study reported by Vershalee Shukla, MD, at the International Association for the Study of Lung Cancer’s (IASLC) North America ...

symptom management

Romiplostim for Patients With Chemotherapy-Induced Thrombocytopenia

In a single-center phase II study reported in the Journal of Clinical Oncology, Soff et al found that treatment with romiplostim was effective in rapidly correcting chemotherapy-induced thrombocytopenia, with maintenance treatment being effective in reducing risk of recurrent chemotherapy-induced...

lung cancer

RELAY Trial: Addition of Ramucirumab to Erlotinib in Previously Untreated, EGFR-Mutated Advanced NSCLC

As reported in The Lancet Oncology by Nakagawa et al, the phase III RELAY trial has shown that the addition of the VEGFR2 inhibitor ramucirumab to the EGFR inhibitor erlotinib improved progression-free survival in treatment-naive, advanced EGFR-mutated non–small cell lung cancer (NSCLC). Study...

BRAF and MEK Inhibition in Advanced Melanoma With Rare BRAF Mutations

In a study reported in the Journal of Clinical Oncology, Menzer et al found that combined BRAF/MEK inhibitor therapy appeared to be more active than single-inhibitor therapy in advanced melanoma with rare BRAF mutations. Study Details The study involved data from 103 patients with advanced melanoma ...

Expert Point of View: Pilar Garrido, MD, PhD

At a press conference at the European Society for Medical Oncology (ESMO) Congress 2019, Pilar Garrido, MD, PhD, of Ramon y Cajal University Hospital, Madrid, commented on the FLAURA trial: “These results are good news for patients with lung cancer, which is the most common cause of cancer deaths. ...

lung cancer

FLAURA Trial: First-Line Osimertinib Improves Overall Survival in EGFR-Mutated Advanced Lung Cancer

First-line treatment with osimertinib extended overall survival compared with the older tyrosine kinase inhibitors gefitinib and erlotinib in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to late-breaking final overall survival results of the phase III FLAURA...

Expert Point of View: Lizza E. Hendriks, MD, PhD

Formal discussant of the ASCEND-7 trial, Lizza E. Hendriks, MD, PhD, of the Maastricht University Medical Center, The Netherlands, said that up to 50% of patients with non–small cell lung cancer (NSCLC) will develop central nervous system (CNS) metastases, and these patients can have poor quality...

lung cancer

Ceritinib Active in Treating Brain Metastases in Non–Small Cell Lung Cancer

The ALK inhibitor ceritinib demonstrated efficacy in patients with ALK-positive non–small cell lung cancer (NSCLC) and active brain metastases, according to the results of the ASCEND-7 trial reported at the European Society for Medical Oncology (ESMO) Congress 2019.1 Substantial intracranial...

solid tumors

Anti-GD2 Monoclonal Antibody Plus Induction Chemotherapy in High-Risk Neuroblastoma

A phase II study evaluating whether combining an investigational anti-GD2 monoclonal antibody with induction chemotherapy improved outcomes in children with newly diagnosed high-risk neuroblastoma found that the therapy significantly improved 2-year event-free survival. Furman et al published the...

breast cancer
cost of care

Deviation From NCCN Guidelines May Result in Greater Costs for Patients With Metastatic Breast Cancer

A study published by Williams et al in JNCCN—Journal of the National Comprehensive Cancer Network found that direct costs for patients with metastatic breast cancer increased when their treatment differed from recommendations found in the NCCN Clinical Practice Guidelines in Oncology® (NCCN...

gastroesophageal cancer
immunotherapy

Nivolumab vs Chemotherapy in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

As reported in The Lancet Oncology by Kato and colleagues, the phase III ATTRACTION-3 trial conducted in predominantly Asian patients has shown a survival benefit with nivolumab vs paclitaxel or docetaxel in patients with advanced esophageal squamous cell carcinoma who were refractory to or...

hematologic malignancies
issues in oncology

High Blood Pressure and Cardiac Adverse Events in Patients Treated With Ibrutinib

Over half of patients treated with the Bruton’s tyrosine kinase inhibitor ibrutinib developed new or worsened high blood pressure within 6 months of starting the medication, according to a study published by Dickerson et al in Blood. The analysis is also the first to tie ibrutinib-related...

issues in oncology
lymphoma

Effect of Race and Ethnicity on Survival in Pediatric and Adolescent Hodgkin Lymphoma

In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Kahn et al found that event-free survival in pediatric and adolescent patients with Hodgkin lymphoma was similar by race and ethnicity in COG trials, but that adjusted overall survival was better in white...

colorectal cancer

Colorectal Cancer Screening With Fecal Immunochemical Testing, Sigmoidoscopy, or Colonoscopy for Patients Aged 50 to 79 Years Old

As reported in The British Medical Journal (BMJ) by Helsingen et al, a clinical practice guideline on colorectal cancer screening published as a BMJ Rapid Recommendations guideline indicates that previously unscreened individuals aged 50 to 79 years old with 15-year colorectal cancer risk of ≥ 3%...

sarcoma

Maintenance Chemotherapy Improves Survival in High-Risk Rhabdomyosarcoma

In the phase III RMS 2005 trial reported by Gianni Bisogno, MD, and colleagues in The Lancet Oncology, maintenance vinorelbine and low-dose continuous cyclophosphamide was associated with nonsignificant improvement in disease-free survival and significantly improved overall survival vs no further...

prostate cancer

Expert Point of View: Gert de Meerleer, MD

Commenting on both RADICALS-RT and the meta-analysis, formal discussant Gert de Meerleer, MD, of the University Hospital, Leuven, Belgium, stated: “A big applause for these trials. I agree with both conclusions and congratulate both groups of authors for finding noncommercial funding.” Dr. de...

prostate cancer

Studies Suggest Early Salvage Radiotherapy May Be Preferable to Adjuvant Radiotherapy After Prostatectomy

Early salvage radiotherapy appears to be a better choice after radical prostatectomy for men with prostate cancer than adjuvant radiotherapy, according to late-breaking results from the ­RADICALS-RT trial and the ARTISTIC meta-analysis of three trials that included RADICALS-RT. Observation after...

palliative care

Expert Point of View: Paul B. Jacobsen, PhD, FASCO

Paul B. Jacobsen, PhD, FASCO, Associate Director of the National Cancer Institute’s Division of Cancer Control and Population Science’s Healthcare Delivery Research Program, said that this study exemplifies the type of work that is needed to more broadly and rapidly translate promising research...

palliative care

Community Health Workers May Improve Value of End-of-Life Cancer Care

The results of simple interventions involving community health workers suggest that improvements in value-based cancer care need not come from health-care professionals. According to data presented at the 2019 ASCO Quality Care Symposium,1 reliance upon community health workers trained to assess...

breast cancer
genomics/genetics

ASCO Breakthrough: Breast Cancer Gene Expression Signature May Help Predict Recurrence Postradiotherapy

Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of...

genomics/genetics

ASCO Breakthrough: Effect of ATM Mutations on Response to Radiotherapy

Somatic mutations of DNA damage repair genes like ATM and BRCA1 or BRCA2 may result in poor disease prognosis and chemotherapy resistance. However, a study by Lee et al presented at ASCO Breakthrough: A Global Summit for Oncology Innovators (Abstract 130) investigated the possibility that these...

lung cancer

ASCO Breakthrough: Computer-Aided Diagnosis System for Detecting Lung Nodule Locations and Characteristics

A computer-aided diagnosis system using deep-learning analysis to detect lung lesion locations and quantitatively characterize the lesions on computed tomography (CT) images offered a fast and convenient approach for assisting radiologists in the diagnosis of lung nodule pathologies. These findings ...

solid tumors

Plasma miR371 Expression as a Biomarker for Active Germ Cell Malignancy

In a study reported in the Journal of Clinical Oncology, Nappi et al showed that plasma microRNA miR371 expression was associated with high specificity and positive predictive values in predicting active germ cell malignancy. Study Details The study included 111 patients with a history of or newly ...

prostate cancer

Acute Toxicity With Intensity-Modulated Fractionated Radiotherapy vs Stereotactic Body Radiotherapy for Prostate Cancer

In an analysis from the phase III PACE-B trial reported in The Lancet Oncology, Brand et al found that shortened treatment courses with stereotactic body radiotherapy did not increase gastrointestinal or genitourinary acute toxicity vs intensity-modulated fractionated radiotherapy in low-risk to...

integrative oncology

Addressing the Gap in Integrative Oncology Education

In 2018, the University of Michigan Medical School in Ann Arbor launched the Integrative Oncology Scholars Program, with the goal of teaching oncology health-care providers how to evaluate the scientific evidence on the efficacy and safety of complementary therapies for patients with cancer. The...

prostate cancer
integrative oncology

Mindfulness Training for Men Diagnosed With Prostate Cancer Who Are on Active Surveillance

GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. The ASCO Post’s Integrative Oncology series is intended to facilitate the...

colorectal cancer

Parenchymal-Sparing Hepatectomy for Colorectal Cancer Liver Metastases

In a meta-analysis published by Deng et al in Cancer Medicine, researchers found parenchymal-sparing hepatectomy was associated with better perioperative outcomes vs extended hepatectomy for the treatment of colorectal cancer liver metastases, without compromising long-term oncologic outcomes. The...

colorectal cancer

Effect of Tumor Sidedness and Molecular Alterations on Outcomes in Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Morano et al assessed prognostic/predictive role of tumor sidedness and presence of uncommon molecular alterations in anti-EGFR treatment primary resistance in patients with RAS/BRAF wild-type metastatic colorectal cancer. Study Details The...

Advertisement

Advertisement



Advertisement